Express Healthcare
Home  »  News  »  Dassault Systèmes hosts ‘The World After: From Things to Life 2020’

Dassault Systèmes hosts ‘The World After: From Things to Life 2020’

0 174
Read Article

The virtual conference focussed on transforming, digitalising life sciences industry in India, which is undergoing core shifts in business processes, manufacturing operations to make it more agile, adaptable

Dassault Systèmes recently hosted ‘The World After: From Things to Life 2020’, a one-of-a-kind virtual conference that provided in-depth insights into the vast potential of the life sciences industry in India. With a deep understanding of the current challenges facing pharmaceutical, biotech and medical device companies, and the patient care sector, Dassault Systèmes hosted the event as part of its commitment to help advance the pace of discovery of new drugs and medicines and deliver holistic, superior patient and physician-centric experiences.

‘The World After – From Things to Life 2020’ focussed on transforming and digitalising the life sciences industry in India, which is undergoing core shifts in business processes and manufacturing operations to make it more agile and adaptable, reinventing the value chain, capitalising knowledge and strategic planning, adhering to regulatory frameworks, and introducing futuristic and advanced technological solutions.

Addressing the business challenges of the life sciences industry, Dassault Systèmes demonstrated the ‘License to Cure for Biopharma’, ‘ONE Lab’, and ‘Accelerated Device’ industry solution experiences based on the 3DEXPERIENCE platform.  In the tracks of the virtual event, several global and local life sciences industry experts and start-ups shared their experiences.

The pharma segment of the event covered topics like digital continuity in the pharmaceutical industry, revolutionising the drug development process with artificial intelligence, design and development of SARS-CoV-2 main protease inhibitors, optimising laboratories and leveraging knowledge to improve time to market. Pharma and biopharma companies are moving towards unified platforms that help in drug research and discovery enhancing the ecosystem- research, development, manufacturing and quality and compliance. “Dassault Systèmes’ solution for quality control labs greatly reduced data input, transcription, and integrity validation efforts increased the overall productivity of the lab,” said Ashok Nayak, CIO, IPCA Laboratories.

The patient care segment in the event discussed ‘In-Silico in healthcare’, optimising efficacy and safety for medical devices, simulation-driven new product development (NPD), simulation for understanding the functional dynamics of the brain and therapeutic stimulations using AI. The patient care sector is changing rapidly with a focus on improving patient outcomes and a shift from intermittent treatments to a continuous engagement driven by simulation technologies. “Multiphysics simulation capabilities have helped in the indigenous research and development of minimally invasive coronary stent systems as well as in maximising their life and performance,” said Dr Ramanan Lakshminarayanan, Chief Technology Officer, Sahajanand Medical Technologies.

The medical devices segment in the event highlighted faster time to market of innovative medical devices, and key technology solutions adopted in the diagnostics segment. Medical device manufacturers are moving away from point solutions for mechanical and electrical design, simulation, product data management (PDM) and technical communication, and toward integrated product development platforms to introduce product faster into the market and improve the overall performance and reliability, which is always the big challenge for them. “Medical device manufacturers have to embrace digital technology to overcome the challenges in the manufacturing, product delivery, supply chain etc., which used to be an option in the past; now it is a must to sustain in the market and be innovative,” said Vishwaprasad Alva, Managing Director, Skanray.

‘The World After – From Things to Life 2020’ also featured the 3DEXPERIENCE playground, which showcased innovations on industry-leading brands like SOLIDWORKS, BIOVIA and SIMULIA with virtual experiences and technology demos of the Internet of Things, artificial intelligence, machine learning and data analytics applicable in the life sciences industry.

“We intend to be a catalyst and technology enabler behind all the new opportunities evolving in the life sciences industry in India,” said Deepak NG, Managing Director, Dassault Systemes, India. “We are born out of science and expertise in engineering. We want to bridge medical science and engineering into the domains of manufacturing of medical devices, to offering scientific applications on the 3DEXPERIENCE platform for drug research, discovery and manufacturing, to simulating treatments. Earlier this year, Dassault Systèmes announced its strategic direction for the coming years, extending its focus from things to life.  We want to transform how people are cured and help them live a better life.”

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More